Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer - Cancer Currents Blog National Cancer Institute sent this bulletin at 05/28/2020 10:33 AM EDT Having trouble viewing this email? View it as a Web page. You are subscribed to Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Recent posts are listed below. Sacituzumab Govitecan Approved for Metastatic Triple-Negative Breast Cancer 05/28/2020 FDA has approved sacituzumab govitecan (Trodelvy) for the treatment of triple-negative breast cancer that has spread to other parts of the body. Under the approval, patients must have already undergone at least two prior treatment regimens.
